Bulk Inquiry
AZD5363 dihydrochloride
- Capivasertib
- Parent CAS: 1143532-39-1
- Soluble in water and DMSO
- MF: C21H25ClN6O2.2HCl
- MW: 501.84
Description
AZD5363 dihydrochloride (Capivasertib) is an orally bioavailable, selective and potent AKT/protein kinase B inhibitor with low-nanomolar activity against AKT pathway signaling.
AKT integrates growth factor and PI3K signals to control survival, metabolism, proliferation and therapy resistance. AZD5363 is used to study AKT-dependent signaling in oncology models and to evaluate pathway inhibition downstream of PI3K activation.
Key Features
- Potent AKT/protein kinase B inhibitor
- Targets PI3K-AKT survival and metabolism signaling
- Orally bioavailable and water-soluble research compound
- Useful for studying AKT-dependent resistance mechanisms
Applications
- AKT phosphorylation and pathway assays
- PI3K-AKT-mTOR signaling research
- Cancer cell survival and proliferation studies
- Combination-treatment and resistance model research
More Information
| Parent CAS No. | 1143532-39-1 |
|---|---|
| Chemical Name | (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide dihydrochloride |
| MFCD | N.A. |
| Short Description | Akt inhibitor |
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1239 | Deguelin |
From $121.00 |
| 1602 | PF 4708671 |
From $121.00 |
| 1663 | Perifosine |
From $93.50 |
| 1684 | MK 2206 dihydrochloride |
From $88.00 |
| 1685 | YS 49 |
From $148.50 |
| 1729 | GSK 690693 |
From $143.00 |
| 1790 | SC 66 |
From $77.00 |
| 1870 | PHT 427 |
From $82.50 |
| 1903 | DG2 |
From $104.50 |
| 2166 | AT 13148 dihydrochloride |
From $77.00 |
| 2460 | GSK 2110183 hydrochloride |
From $115.50 |
| 2464 | LY 2584702 tosylate |
From $137.50 |
| 2507 | SC 79 |
From $82.50 |
| 2540 | Akt Inhibitor VIII |
From $104.50 |
| 3343 | ML-9 hydrochloride |
From $66.00 |
| 3850 | M2698 |
From Inquiry |
| 3958 | Uprosertib |
From Inquiry |
| 4037 | GDC-0068 |
From Inquiry |
